🇺🇸 FDA
Pipeline program

SGT-212

SGT-212-101

Phase 1 small_molecule active

Quick answer

SGT-212 for Friedreich's Ataxia (FA) is a Phase 1 program (small_molecule) at Solid Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Solid Biosciences
Indication
Friedreich's Ataxia (FA)
Phase
Phase 1
Modality
small_molecule
Status
active

Clinical trials